腎臟生物標記市場－全球產業規模、佔有率、趨勢、機會及預測（按產品類型、技術、最終用戶、地區和競爭格局分類，2021-2031年）

全球腎臟生物標記市場預計將從 2025 年的 14.1 億美元成長到 2031 年的 21.5 億美元，複合年成長率為 7.28%。

腎臟生物標記是可測量的生物學指標，可在血液、尿液或組織中檢測到，對於評估腎功能和識別病理至關重要。推動這一市場擴張的關鍵因素包括全球慢性腎臟病發病率的上升以及人口老化導致腎衰竭風險增加。此外，與傳統功能性檢測相比，診斷準確性的提升具有重要的臨床意義，這也加速了這些先進工具的應用。為了說明腎臟疾病帶來的健康負擔之重，國際腎臟病學會估計，到2024年，全球將有約8.5億人患有腎臟疾病，凸顯了對先進診斷解決方案的迫切需求。

儘管市場成長前景強勁，但新診斷檢測方法的嚴格監管核准流程仍構成重大障礙。檢驗新型生物標記是否符合衛生監管機構制定的嚴格分析和臨床性能標準十分複雜，往往會延緩商業化進程並增加研發成本。因此，這些監管障礙阻礙了企業進入市場，並阻礙了有前景的研究成果轉化為可上市的臨床解決方案，從而減緩了市場整體擴張速度。

市場促進因素

糖尿病和高血壓盛行率的不斷上升是全球腎臟生物標記市場的主要驅動力。這些合併症會逐漸損害腎血管，因此迫切需要靈敏的生物標記物，以便在發生不可逆的功能衰退之前及早發現損傷。因此，醫療機構正優先考慮實施先進的診斷方案，以有效監測這些高風險患者群體。根據美國疾病管制與預防中心 (CDC) 於 2024 年 5 月發布的《美國慢性慢性腎臟病》報告，糖尿病和高血壓是腎衰竭的主要原因，佔所有新增病例的三分之二。這種臨床負擔給醫療保健系統帶來了巨大的經濟壓力，因此亟需開發高效的診斷解決方案。為了強調這一經濟促進因素，美國國立衛生研究院 (NIH) 在其 2024 年 USRDS 年度數據報告中指出，參加 Medicare計量型支付系統的慢性腎臟病成年患者的醫療費用將在 2023 年達到 1411 億美元。

同時，人工智慧與新型預後檢測技術的融合正推動該領域邁向精準醫療。利用機器學習分析體液生物標記的先進平台，能夠提供超越傳統功能性檢測的風險分層，使臨床醫生能夠更準確地預測疾病進展。有利的商業性獎勵進一步推動了這項技術發展。例如，Renalytics公司在2024年11月發布的「2024會計年度全年審核報告」中指出，其獲得FDA批准的腎臟診斷測試kidneyintelX.dkd，每份可報告結果的Medicare報銷高達950美元。如此高的報銷額凸顯了下一代診斷技術的巨大市場價值，並鼓勵業界持續投資開發非侵入性、人工智慧驅動的腎臟解決方案。

市場挑戰

嚴格的監管核准流程是腎臟生物標記領域發展的重要障礙。檢驗新型生物標記以滿足衛生監管機構嚴苛的分析和臨床性能標準需要耗費大量資源。這些要求顯著延長了產品開發週期，並增加了整體成本。因此，企業面臨更大的財務風險，降低了其投資新型診斷檢測方法的意願，並延緩了可能取代傳統檢測方法的工具的推出。

監管瓶頸直接限制了市場發展，限制了先進檢測方法的應用，而這些方法對於彌補腎臟疾病診斷的巨大缺口至關重要。由於無法快速將有效的生物標記推向市場，目前仍依賴靈敏度低的過時檢測方法，導致相當一部分患者無法及時診斷。為了說明這一診斷缺口的嚴重性，美國國家腎臟基金會報告稱，到2024年，約90%的慢性腎臟病病患者仍將無法確診。這項數據表明，由於新型診斷方案的監管核准延遲，市場存在巨大的未滿足需求。

市場趨勢

即時檢測（尤其是基於智慧型手機的尿液檢查）的普及，正透過分散式診斷管道重塑市場格局。這一趨勢旨在解決檢測普及率低的問題，尤其是在醫療資源匱乏、後勤障礙阻礙診斷的地區。在家即可進行臨床級別的蛋白尿尿液檢查，使醫療系統能夠監測先前難以觸及的高風險族群。美國國家腎臟效用在2025年8月發布的報告《消除慢性腎臟病檢測中的差異》中指出，一項家庭檢測舉措篩檢了1496名高風險患者，其中50%的患者存在蛋白尿。這凸顯了遠距離診斷在發現未確診腎臟疾病的潛力。

同時，隨著新型生物標記在急性腎損傷（AKI）早期檢測的應用，重症監護品質正在不斷提高，這些標記取代了血清肌酸酐等延遲指標。醫院正在整合能夠指示功能衰竭前結構性損傷的生物標記，從而實現加護病房的快速干預。這種能力正在推動腎臟即時監測的發展。例如，正如2025年8月發表於BioSpace的報導「ProNephro AKI (NGAL): 一種急性腎損傷早期檢測方法」中所述，BioPorto公司宣布推出一種可在48至72小時內識別中度至重度AKI風險患者的檢測方法。這個快速檢測窗口對於及時實施適當的保護策略至關重要。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球腎臟生物標記市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品類型（功能性生物標記、血清肌酸酐、血清胱Cystatin C、尿液白蛋白、上調蛋白、嗜中性白血球明膠酶相關脂質運載蛋白（NGAL）、腎損傷分子-1、白細胞介素-18、其他）
  • 依技術（酵素免疫分析法（ELISA）、顆粒增強濁度免疫檢測（PETIA）、比色檢測法、化學冷光酵素免疫分析法（CLIA）、液相層析法-質譜聯用（LC-MS））
  • 依最終使用者（醫院/診所、診斷檢查室、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美腎臟生物標記市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲腎臟生物標記市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區腎臟生物標記市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲腎臟生物標記市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲腎臟生物標記市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球腎臟生物標記市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Abbott Laboratories
• Beckman Coulter Inc.
• bioMerieux SA
• BioPorto A/S
• Bio-Rad Laboratories Inc.
• Enzo Biochem Inc.
• F. Hoffmann-La Roche AG
• PerkinElmer Inc.
• Randox Laboratories Ltd.
• Siemens AG
• Thermo Fisher Scientific Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Renal Biomarkers Market is projected to expand from USD 1.41 Billion in 2025 to USD 2.15 Billion by 2031, reflecting a compound annual growth rate of 7.28%. Renal biomarkers, which are measurable biological indicators detectable in blood, urine, or tissue, are essential for evaluating kidney function and identifying pathological states. The primary factors driving this market expansion include the rising global incidence of chronic kidney disease and an aging demographic that is increasingly prone to renal insufficiency. Additionally, the critical clinical need for improved diagnostic accuracy to replace traditional functional tests is accelerating the adoption of these advanced tools. To demonstrate the scale of this health burden, the International Society of Nephrology estimated in 2024 that approximately 850 million individuals worldwide were affected by kidney disease, highlighting the urgent necessity for sophisticated diagnostic solutions.

Despite this strong growth outlook, the market encounters a significant obstacle regarding the rigorous regulatory approval process for new diagnostic assays. The complexity involved in validating novel biomarkers to meet the stringent analytical and clinical performance standards set by health authorities often leads to delays in commercialization and inflated development costs. Consequently, these regulatory hurdles can discourage enterprises from entering the sector and impede the transition of promising research candidates into commercially available clinical solutions, thereby slowing the overall pace of market expansion.

Market Driver

The escalating prevalence of diabetes and hypertension serves as the primary catalyst for the Global Renal Biomarkers Market. Because these comorbidities progressively damage renal vasculature, there is a critical need for sensitive biomarkers capable of detecting early injury before irreversible decline sets in. As a result, healthcare providers are prioritizing advanced diagnostic panels to effectively monitor these high-risk patient groups. According to the Centers for Disease Control and Prevention's 'Chronic Kidney Disease in the United States' report from May 2024, diabetes and high blood pressure are the leading causes of kidney failure, accounting for two out of every three new cases. This clinical burden places immense financial strain on healthcare systems, necessitating efficient diagnostic solutions. Highlighting this economic driver, the National Institutes of Health noted in the 2024 USRDS Annual Data Report that the cost of care for adults with Medicare fee-for-service coverage and chronic kidney disease rose to $141.1 billion in 2023.

Concurrently, the integration of artificial intelligence with novel prognostic assays is propelling the sector toward precision medicine. Advanced platforms utilizing machine learning to analyze fluid biomarkers now offer risk stratification superior to traditional functional tests, enabling clinicians to predict disease progression with greater accuracy. This technological evolution is further supported by favorable commercial incentives that fuel adoption. For instance, Renalytix reported in its 'Audited Full Year Fiscal 2024 Results' in November 2024 that its FDA-authorized kidneyintelX.dkd test secured a Medicare reimbursement rate of $950 per reportable result. Such substantial reimbursement highlights the high market value of next-generation diagnostics and encourages sustained industrial investment in developing non-invasive, AI-driven renal solutions.

Market Challenge

The stringent regulatory approval process constitutes a substantial barrier to the progress of the renal biomarkers sector. Validating new biomarkers to satisfy the rigorous analytical and clinical performance standards demanded by health authorities requires extensive resources. These requirements significantly prolong the timeline for product development and increase overall expenditures. As a result, companies face heightened financial risks, which discourages investment in novel diagnostic assays and delays the introduction of tools that could replace conventional testing methods.

This regulatory bottleneck directly restricts the market by limiting the availability of advanced detection methods needed to address the massive diagnostic gap in renal care. The inability to rapidly bring effective biomarkers to market perpetuates the reliance on older, less sensitive tests, leaving a significant portion of the patient population without timely detection. To highlight the extent of this diagnostic deficit, the National Kidney Foundation reported in 2024 that approximately 90 percent of individuals with chronic kidney disease remained undiagnosed. This statistic indicates a severe market need that remains unmet due to the slow pace of regulatory clearance for new diagnostic solutions.

Market Trends

The expansion of point-of-care testing, particularly smartphone-based urinalysis, is reshaping the market by decentralizing diagnostic access. This trend addresses low adherence to laboratory screenings, especially among underserved populations where logistical barriers impede diagnosis. By enabling clinical-grade albuminuria testing at home, healthcare systems can monitor previously unreachable at-risk individuals. Validating this utility, the National Kidney Foundation reported in its August 2025 paper, 'Closing Gaps in Chronic Kidney Disease Detection', that an at-home testing initiative successfully screened 1,496 high-risk patients, with 50 percent showing evidence of albuminuria. This underscores the potential of remote diagnostics to uncover undiagnosed renal conditions.

Simultaneously, the adoption of novel biomarkers for early acute kidney injury (AKI) detection is advancing critical care by superseding lagging indicators like serum creatinine. Hospitals are integrating biomarkers that signal structural damage prior to functional loss, facilitating rapid intervention in intensive care units. This capability is driving a move toward real-time renal monitoring. For instance, as detailed in the BioSpace article 'ProNephro AKI (NGAL), early detection test for Acute Kidney Injury' from August 2025, BioPorto announced the commercial availability of a test that identifies patients at risk of moderate-to-severe AKI within 48 to 72 hours. This rapid detection window is crucial for implementing timely protective strategies.

Key Market Players

• Abbott Laboratories
• Beckman Coulter Inc.
• bioMerieux SA
• BioPorto A/S
• Bio-Rad Laboratories Inc.
• Enzo Biochem Inc.
• F. Hoffmann-La Roche AG
• PerkinElmer Inc.
• Randox Laboratories Ltd.
• Siemens AG
• Thermo Fisher Scientific Inc

Report Scope

In this report, the Global Renal Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Renal Biomarkers Market, By Product Type

• Functional Biomarker
• Serum Creatinine
• Serum Cystatin C
• Urine Albumin
• Up-regulated Protein
• Neutrophil Gelatinase-Associated Lipocalin (NGAL)
• Kidney Injury Molecule-1
• INTERLEUKIN-18
• Others

Renal Biomarkers Market, By Technique

• Enzyme-linked Immunosorbent Assay (ELISA)
• Particle-enhanced Turbidimetric Immunoassay (PETIA)
• Colorimetric Assay
• Chemiluminescent Enzyme Immunoassay (CLIA)
• Liquid Chromatography Mass Spectrometry (LC-MS)

Renal Biomarkers Market, By End user

• Hospitals & Clinics
• Diagnostic Laboratory
• Others

Renal Biomarkers Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Renal Biomarkers Market.

Available Customizations:

Global Renal Biomarkers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Renal Biomarkers Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Functional Biomarker, Serum Creatinine, Serum Cystatin C, Urine Albumin, Up-regulated Protein, Neutrophil Gelatinase-Associated Lipocalin (NGAL), Kidney Injury Molecule-1, INTERLEUKIN-18, Others)
  • 5.2.2. By Technique (Enzyme-linked Immunosorbent Assay (ELISA), Particle-enhanced Turbidimetric Immunoassay (PETIA), Colorimetric Assay, Chemiluminescent Enzyme Immunoassay (CLIA), Liquid Chromatography Mass Spectrometry (LC-MS))
  • 5.2.3. By End user (Hospitals & Clinics, Diagnostic Laboratory, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Renal Biomarkers Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Technique
  • 6.2.3. By End user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Renal Biomarkers Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Technique
      • 6.3.1.2.3. By End user
  • 6.3.2. Canada Renal Biomarkers Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Technique
      • 6.3.2.2.3. By End user
  • 6.3.3. Mexico Renal Biomarkers Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Technique
      • 6.3.3.2.3. By End user

7. Europe Renal Biomarkers Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Technique
  • 7.2.3. By End user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Renal Biomarkers Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Technique
      • 7.3.1.2.3. By End user
  • 7.3.2. France Renal Biomarkers Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Technique
      • 7.3.2.2.3. By End user
  • 7.3.3. United Kingdom Renal Biomarkers Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Technique
      • 7.3.3.2.3. By End user
  • 7.3.4. Italy Renal Biomarkers Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Technique
      • 7.3.4.2.3. By End user
  • 7.3.5. Spain Renal Biomarkers Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Technique
      • 7.3.5.2.3. By End user

8. Asia Pacific Renal Biomarkers Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Technique
  • 8.2.3. By End user
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Renal Biomarkers Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Technique
      • 8.3.1.2.3. By End user
  • 8.3.2. India Renal Biomarkers Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Technique
      • 8.3.2.2.3. By End user
  • 8.3.3. Japan Renal Biomarkers Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Technique
      • 8.3.3.2.3. By End user
  • 8.3.4. South Korea Renal Biomarkers Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Technique
      • 8.3.4.2.3. By End user
  • 8.3.5. Australia Renal Biomarkers Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Technique
      • 8.3.5.2.3. By End user

9. Middle East & Africa Renal Biomarkers Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Technique
  • 9.2.3. By End user
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Renal Biomarkers Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Technique
      • 9.3.1.2.3. By End user
  • 9.3.2. UAE Renal Biomarkers Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Technique
      • 9.3.2.2.3. By End user
  • 9.3.3. South Africa Renal Biomarkers Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Technique
      • 9.3.3.2.3. By End user

10. South America Renal Biomarkers Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Technique
  • 10.2.3. By End user
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Renal Biomarkers Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Technique
      • 10.3.1.2.3. By End user
  • 10.3.2. Colombia Renal Biomarkers Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Technique
      • 10.3.2.2.3. By End user
  • 10.3.3. Argentina Renal Biomarkers Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Technique
      • 10.3.3.2.3. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Renal Biomarkers Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abbott Laboratories
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Beckman Coulter Inc.
• 15.3. bioMerieux SA
• 15.4. BioPorto A/S
• 15.5. Bio-Rad Laboratories Inc.
• 15.6. Enzo Biochem Inc.
• 15.7. F. Hoffmann-La Roche AG
• 15.8. PerkinElmer Inc.
• 15.9. Randox Laboratories Ltd.
• 15.10. Siemens AG
• 15.11. Thermo Fisher Scientific Inc

16. Strategic Recommendations

17. About Us & Disclaimer